Vir Biotechnology (VIR) Change in Accured Expenses (2018 - 2026)

Vir Biotechnology's Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$17.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 195.62% year-over-year to -$17.2 million; the TTM figure through Mar 2026 stood at -$44.7 million (down 179.6% YoY), while the FY2025 annual figure was -$9.5 million, up 85.15% from the prior year.
• Change in Accured Expenses came in at -$17.2 million for Q1 2026 at Vir Biotechnology, down from $10.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $433.6 million in Q1 2022 to a low of -$288.2 million in Q2 2022.
• A 5-year average of -$27.4 million and a median of -$23.5 million in 2025 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 2402.84% in 2022 and fell as far as 8228.76% in 2022.
• Vir Biotechnology's Change in Accured Expenses stood at -$80.7 million in 2022, then surged by 48.02% to -$41.9 million in 2023, then decreased by 15.65% to -$48.5 million in 2024, then jumped by 120.84% to $10.1 million in 2025, then sank by 270.46% to -$17.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$17.2 million, $10.1 million, and -$14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison